🟢 NTHI is trading 5.1% up today as investors weigh UAE IND approval against share issuance concerns

NTHI is trading 5.1% up at $4.74 as investors reassess the impact of a potential $75 million share issuance against positive regulatory developments for its CNS cancer program.

• The stock saw an earlier selloff driven by dilution concerns tied to the proposed financing overhang.
• Renewed interest follows Wednesday’s news of a second UAE IND approval for NEO100, which expands the company's clinical footprint in CNS cancer.
• After-hours buying suggests that regulatory progress is beginning to overshadow the immediate impact of the share issuance news.